射频消融治疗肾癌现状

近年来射频消融日益广泛应用于肾癌治疗,随着操作技术的不断发展,已在临床上取得显著的近期疗效,具有微创、安全、操作方便、并发症轻、患者痛苦少等特点。其未来发展的关键在于改进电极针,提高射频技术,联合c其他疗法等以提高疗效,并建立更合理的包括影像检查技术在内的疗效评价标准。     

Magnetic resonance-guided percutaneous laser ablation of uterine fibroids

Laser ablation of uterine fibroids using a percutaneous approach under local anesthetic in an open magnetic resonance (MR) scanner was performed in 12 symptomatic women awaiting hysterectomy. Accurate laser fiber placement was assisted by the use of an MR needle tracking system, as well as laser heat dissipation monitored during treatment by a real-time imaging processor. This day case procedure was well tolerated by all women, with eight women subsequently declining their planned surgery. Follow-up measurements of treated fibroid volume by MRI demonstrated a mean decrease of 37.5% at 3 months. This novel minimally invasive approach offers an alternative to surgery for women with fibroids, but longer follow-up is required to ascertain maximal fibroid shrinkage and to compare outcome with traditional surgery.     

CT-guided percutaneous radiofrequency ablation of spleen: a preliminary study

OBJECTIVE: The objective of our study was to evaluate the technical feasibility, safety, and changes of platelet counts of CT-guided percutaneous radiofrequency ablation of normal spleen in a porcine model. CONCLUSION: It is feasible and safe to perform CT-guided percutaneous radiofrequency ablation of the spleen in a pig. Although further study is still required in clinical applications, this method can be a minimally invasive and effective therapeutic technique in patients with hypersplenism.     

Comparison of expandable electrodes in percutaneous radiofrequency ablation of renal cell carcinoma

OBJECTIVE: To compare two different expandable electrodes in radiofrequency ablation of renal cell carcinoma. METHODS: Percutaneous ablation was performed at two centers using either an expandable 7F umbrella-shaped LeVeen probe (diameter 2-4 cm) and a 200-W generator (group A), or an expandable Starburst XL electrode with a 150-W generator (group B). From each center, eight patients with one tumor each were matched retrospectively with regard to tumor volume, which was 9.71+/-6.43 cm3 for group A and 8.74+/-4.35 cm3 for group B (mean tumor diameter: 2.47+/-0.9 cm versus 2.50+/-0.4 cm, respectively). An unpaired t-test showed no significant difference in tumor volume between the two groups (p=0.820). RESULTS: Sixteen patients with 16 tumors were treated. The primary technical success of radiofrequency ablation was 94% (15 of 16 patients). After retreatment of residual tumor in one patient from group B, secondary technical success was 100%. No major complications were observed. The resulting mean volume of the almost spherical necroses was 21.1+/-9.1 cm3 versus 14.6+/-6.7 cm3 for groups A and B (diameter of necrosis: 3.5+/-0.7 cm versus 3.1+/-0.6 cm, respectively). A Mann-Whitney U-test showed no significant difference in necrosis volume between the two groups (CI [-0.215; 0.471]; p=0.2892). The calculated shape value of S (ratio of length to height of the coagulation necrosis) was 0.9+/-0.1 and 1.0+/-0.1 for groups A and B, respectively. No local recurrence was observed during a mean follow-up of 14.8+/-11.6 months, while extrarenal tumor progression occurred in three patients. CONCLUSIONS: No significant differences in coagulation volume and shape were found after RF ablation of renal cell carcinoma using two different expandable electrodes. To avoid local recurrence, however, accurate placement of probes and appropriate expansion of the electrode is necessary.     

Dual-energy CT in assessing therapeutic response to radiofrequency ablation of renal cell carcinomas

Purpose

To investigate the utility of dual-energy (DE) CT using virtual noncontrast (VNC) and iodine overlay (IO) images to assess therapeutic response to radiofrequency ablation (RFA) for renal cell carcinomas (RCCs).

Materials and methods

In this institutional review board-approved study (with waiver of informed consent), 47 patients with RCCs that underwent DECT after RFA were enrolled in this study. DECT protocols included true noncontrast (TNC), linearly blended DE corticomedullary and late nephrographic phase imaging. Two types of VNC and IO images were derived from corticomedullary and late nephrographic phases, respectively. To predict local tumor progression at RFA site, linearly blended and IO images were analyzed both qualitatively and quantitatively. Contrast-to-noise ratios (CNR) of renal cortex-to-RFA zones were calculated. The overall imaging quality of VNC images was compared with TNC images.

Results

The IO images from corticomedullary and late nephrographic phases showed excellent diagnostic performance (each sensitivity 100% and each specificity 91.5%) for predicting local tumor progression. The degree of enhancement of local tumor progression was not significantly different between linearly blended and IO images (P > 0.05). The mean CT numbers were not significantly different between TNC and VNC images (P > 0.05). In renal cortex-to-RFA site, CNR between linearly blended and IO images was not significantly different (P > 0.05). The VNC imaging quality from the two phases was given a good rating.

Conclusion

VNC and IO images from DECT may allow acceptable diagnostic performance with less radiation exposure as a follow-up imaging tool after RFA for RCC, compared to the linearly blended CT images.     

经皮肾交感神经射频消融术新器械研制及实验研究

目的 探讨新型国产FlashPiontTM多极肾动脉射频消融导管用于经皮肾交感神经射频消融术的可行性及安全性.方法 FlashPiontTM多极肾动脉射频消融导管头端为螺旋形弯曲状,设有4个消融电极.选用健康实验犬10只,均经股动脉鞘管将FlashPiontTM导管送入右肾动脉主干放电消融2次.术后1个月复查肾动脉造影并处死实验犬,作肾动脉交感神经病理学检查.结果 10只实验犬均顺利完成一侧去肾神经术.术后即刻肾动脉造影未见肾动脉狭窄、血栓形成及夹层等并发症;术后1个月复查造影见两侧肾动脉均通畅,未发现肾动脉狭窄、夹层等并发症,组织病理学检查发现肾动脉血管周围交感神经明显坏死.结论 FlashPiontTM多极肾动脉射频消融导管设计合理、操作简单,能安全、有效地消融犬肾交感神经.     

超选择性肾动脉栓塞术联合射频消融治疗肾癌的临床应用

目的 探讨超选择性肾动脉栓塞术联合射频消融(RFA)治疗肾癌的疗效.方法 分析2009年1月至2011年4月9例肾癌患者超选择性肾动脉栓塞联合RFA.患者均在超选择性肾动脉栓塞术后3～7 d,在CT引导下行RFA.术后1个月行肾脏病灶穿刺活检和CT增强检查评价其疗效.结果 9例患者随访1～6个月,未发现.肾脏肿瘤增大,...     

Percutaneous radiofrequency ablation of renal cell carcinomas in patients with solitary kidney: 6 years experience

Objective

In this study we attempt to present our clinical experience in RFA under CT-guidance, in patients with renal cell carcinoma in a solitary kidney.

Material and Method

Between October 2000 and June 2005, 18 patients with solitary kidney and renal cell carcinoma underwent percutaneous CT-guided radiofrequency ablation in our institution. Tumors diameter ranged from 1 to 7 cm and there was no evidence of spread beyond the kidney. The RFA-system used was with expandable needle electrode (7 or 9 arrays). Technical success, recurrence and survival rate and complications were accessed. Patients were available for clinical and laboratory evaluation at a mean follow-up time of 31.2 months (range: 12–72 months).

Results

In all cases the electrode was successfully placed at the lesion. The 18 tumors were treated with totally 24 RFA sessions. In small (1–3 cm) exophytic tumors technical success was 85.7%. Residual disease was totally seen in 6/18 tumors which required a 2nd RFA session. The recurrence rate was 11.1% but no recurrence was noticed in tumors less than 3 cm in diameter. No major complications were observed. Serum creatinine values were normal in 17/18 patients till the 3rd-month follow-up. Survival ranged from 12 to 72 months.

Conclusion

RFA is an acceptable alternative for patients with small RCCs in a solitary kidney, which are not ideal candidates for surgical resection as their renal function must be preserved. They have an immediate solution to their clinical problem, under a minimally invasive therapy with no serious complications.     

Percutaneous radiofrequency ablation of renal cell carcinoma

Conventional curative therapy for renal cell carcinoma has been open nephrectomy. However, several less invasive and/or nephron-sparing procedures have been developed as alternatives in selected patients. The newest of these therapeutic modalities involves percutaneous image-guided ablation with straight or expandable needle applicators that deposit energy. Radiofrequency ablation is the modality for which there is the largest reported experience with percutaneous application, and involves the use of electrical current to generate frictional heating of tissue. Animal studies confirm the ability of radiofrequency ablation to cause regions of necrosis within normal kidney and in VX2 tumors. Clinically, radiofrequency ablation of small renal cell carcinoma is increasingly being performed in selected patients who are not ideal surgical candidates. Results are excellent for small exophytic tumors, but successful treatment is less likely as tumor size increases or the location becomes more central. Complete treatment of most tumors requires one or more overlapping ablations with the needle electrodes positioned so as to cause necrosis in the entire volume of tumor. The number of overlapping ablations and the position of the needle electrodes vary based on tumor size and geometry. For very large tumors, pre-ablation catheter embolization may enhance the results of ablation by decreasing blood flow and perfusion mediated cooling. Following ablation, imaging with CT or MR is performed to assess the result and to diagnose any residual tumor so that it can be treated. Because the tumor remains in situ, imaging follow-up continues indefinitely. The complication rate of radiofrequency ablation is favorable when compared to surgical techniques. Long-term survival data are not yet available.     

Image-guided radiofrequency ablation of renal cell carcinoma

The incidence of renal cell carcinoma is rising with the increased number of incidental detection of small tumours. During the past few years, percutaneous imaging-guided radiofrequency ablation has evolved as a minimally invasive treatment of small unresectable renal tumours offering reduced patient morbidity and overall health care costs. In radiofrequency ablation, thermal energy is deposited into a targeted tumour by means of a radiofrequency applicator. In recent studies, radiofrequency ablation was shown to be an effective and safe modality for local destruction of renal cell carcinoma. Radiofrequency applicator navigation can be performed via ultrasound, computed tomography or magnetic resonance guidance; however, ultrasound seems less favourable because of the absence of monitoring capabilities during ablation. On-line monitoring of treatment outcome can only be performed with magnetic resonance imaging giving the possibility of eventual applicator repositioning to ablate visible residual tumour tissue. Long-term follow-up is crucial to assess completeness of tumour ablation. New developments in ablation technology and radiological equipment will further increase the indication field for radiofrequency ablation of renal cell carcinoma. Altogether, radiofrequency ablation seems to be a promising new modality for the minimally invasive treatment of renal cell carcinoma, which was demonstrated to exhibit high short-term effectiveness.     

Spontaneous regression of pulmonary and adrenal metastases following percutaneous radiofrequency ablation of a recurrent renal cell carcinoma

The spontaneous regression of metastatic lesions from renal cell carcinoma (RCC) is extremely rare, but may be encountered following cytoreductive treatments. We report a case of a recurrent RCC with multiple metastatic lesions which spontaneously regressed after undergoing radiofrequency ablation of the renal tumor.     

Liver abscess after percutaneous radiofrequency ablation for hepatocellular carcinomas: frequency and risk factors

OBJECTIVE: The purpose of this study was to clarify the frequency and risk factors of liver abscess formation after percutaneous radiofrequency ablation in patients with hepatocellular carcinoma. MATERIALS AND METHODS: Over a 4-year period, 603 patients with 831 hepatocellular carcinomas measuring 5 cm or less in maximum diameter who underwent a total of 751 percutaneous radiofrequency ablation procedures were enrolled in this study. We retrospectively reviewed the medical records and analyzed the overall frequency of liver abscess, risk factors for abscess, and clinical features of the patients. The relationships between liver abscess and potential risk factors were analyzed using either generalized estimating equations or multiple logistic regression analysis. RESULTS: Liver abscess developed in 14 tumors of 13 patients after 13 (13/751 [1.7%]) ablation procedures. Generalized estimating equations and multiple logistic regression analysis of various potential risk factors revealed that preexisting biliary abnormality prone to ascending biliary infection (p = 0.0088), tumor with retention of iodized oil from previous transcatheter arterial chemoembolization (p = 0.040), and treatment with an internally cooled electrode system (p = 0.016) were associated with a significant risk of liver abscess formation. No patient died of liver abscess, and all successfully recovered from liver abscess with parenteral antibiotics and percutaneous clearance of pus. CONCLUSION: Although liver abscess formation was infrequent in patients who underwent percutaneous radiofrequency ablation for hepatocellular carcinoma, the patients with significant risk factors-preexisting biliary abnormality prone to ascending biliary infection, tumor with retention of iodized oil, and treatment with an internally cooled electrode system-for liver abscess formation should be closely monitored after treatment.     

Percutaneous radiofrequency ablation of renal cell carcinoma: preliminary results

PURPOSE: To report early results in percutaneous radiofrequency ablation (RFA) of renal cell carcinoma with an expandable RF probe. MATERIAL AND METHODS: In 14 patients (9 male, mean age 67.9 +/- 9.9 years) CT-guided percutaneous radiofrequency ablation of 15 renal cell carcinomas was performed using an expandable LeVeen probe (diameter 2-4 cm) and a 200-watt generator under general anesthesia and CT control. Tumors exceeding a diameter of 3 cm (n=6) were embolized within 24 h prior to RFA. Average tumor size was 3.0 +/- 1.0 cm. RESULTS: RFA was technically successful in all patients, resulting in a mean size of necrosis of 3.7 +/- 0.7 cm. With the exception of one reno-cutaneous fistula, which was successfully treated conservatively, no major complications were observed. No local recurrence was observed (follow-up: 13.9 +/- 12.4 months) while extrarenal tumor progression occurred in four patients. CONCLUSION: Our preliminary data suggest that nephron sparing percutaneous RFA of renal tumors with an expandable RF probe is safe and effective.     

Infectious complications after percutaneous radiofrequency ablation of renal cell carcinoma in patients with ileal conduit

Percutaneous renal radiofrequency (RF) ablation is a safe and minimally invasive treatment for renal cell carcinoma. The most common minor complications are pain, self-limiting hematuria, and postablation syndrome. Major complications are rare and include significant hemorrhage and thermal injury to the ureter. Reports of infectious complications after ablation are uncommon, but increased risks in patients with ileal conduits have been reported. The present report describes two patients with ileal conduits who underwent percutaneous renal RF ablation and developed infectious complications (a renal abscess and a calyceal-cutaneous fistula) despite prophylactic antibiotic treatment.